ClinicalTrials.gg
RecruitingNCT05982925Updated Jun 15, 2026

Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders

An observational study in Multiple Sclerosis, Neuromyelitis Optica and Demyelinating Autoimmune Diseases, CNS, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Icahn School of Medicine at Mount Sinai · Observational

How we know

From the registry’s dates

  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
170
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,192 studies in Multiple Sclerosis with a site in United States — 184 open to participants now, 258 under way, 23 of them phase 3. Multiple Sclerosis · United States.

Planned enrollment
110th of 302
170 · median 100
Started
2022
with 42 others
Observational
302 of 1,192
51 open now
Primary completion
2028-07
later than 177 of 255 live
Registered
1,004th of 1,192
by date

Among the 1,192 studies in Multiple Sclerosis with a site in United States, this one is the 110th largest by planned enrollment of the 302 observational ones that give a count, is one of 43 that started in 2022, is one of 302 observational ones, reaches primary completion later than 177 of the 255 other live ones, and was the 1,004th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

184 of the 1,192 studies in Multiple Sclerosis with a site in United States are open now. Recruiting first, the newest first:

179 more — sign in →

All 184 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,192 studies in Multiple Sclerosis with a site in United States, or all of them as a file.
02

Study summary

In this protocol, a combination of MRI, blood, and cerebrospinal fluid (CSF) analysis will be used to understand the natural history, underlying immunologic mechanisms, and clinical implications of central nervous system (CNS) lesions, in particular lesions in the cerebral cortex, in multiple sclerosis (MS) and other inflammatory and autoimmune disorders affecting the CNS. Patients with these disorders, as well as healthy controls, will undergo baseline clinical evaluation and testing, bloodwork, and MRI, with follow up clinical evaluation, bloodwork, and MRI at years 1, 3, and 6. Additional MRIs may be performed in patients with possible new lesion formation or to compare MRI techniques. Lumbar puncture will be performed on participants who are not currently being treated with disease modifying therapies and who are willing to undergo the procedure.

03

Conditions studied

  • Multiple Sclerosis
  • Neuromyelitis Optica
  • Demyelinating Autoimmune Diseases, CNS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adults with MS or other neuroinflammatory diseases and healthy volunteers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old
  • able to provide consent in English
  • able to undergo MRI

Exclusion criteria

Exclusion Criteria:

  • to MRI
  • pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
170 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • MS Participant

    Adults with multiple sclerosis

  • Control Participant

    Adults without neurologic disease

  • Other Neuroinflammatory Participants

    Adults with a neuroinflammatory disease that is not multiple sclerosis

06

What researchers measure

Primary outcomes

  1. Cortical Lesion Number

    Lesions in the cerebral cortex

    Time frame: at 6 years (end of study)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

Supporting information: Study protocol, Informed consent form

Time frame: Beginning 3 months and ending 5 years following article publication.

Access criteria: Researchers who provide a methodologically sound proposal. Any purpose. Specify Other Mechanism Proposals should be directed to erin.beck@mssm.edu To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Jul 2028, 74 months after the start.

Of 336 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's planned 74 months is above that.

Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2023
First posted
Aug 9, 2023
StartActual
May 6, 2022
Primary completionEst.
Jul 31, 2028
CompletionEst.
Jul 31, 2034
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05982925
Responsible party
Erin Beck (Assistant Professor of Neurology, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Aug 9, 2023
Start date
May 6, 2022
Primary completion
Jul 31, 2028 (estimated)
Completion
Jul 31, 2034 (estimated)
Last update
Jun 15, 2026

Study contacts

Erin S Beck, MD, PhD
Contact
erin.beck@mssm.edu
212-241-2474
Erin S Beck, MD, PhD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion